^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
MDxHealth

i
Other names: OncoMethylome | MDxHealth | NovioGendix | MDx Health | Noviogendix Holding B.V. | OncoMethylome Sciences
Related tests:
Evidence

News

1m
EnGenBio signs strategic partnership MOU with Genolution (NGeneBio Press Release)
"Engenbio...announced on the 13th that it has signed a business agreement with Genolution...Through this business collaboration, NGenBio plans to cooperate with Genolution in launching an expandable system to automate the entire NGS testing workflow, including nucleic acid extraction, library production, and data analysis steps."
Licensing / partnership • Launch
1m
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering (GlobeNewswire)
"MDxHealth SA...announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk of developing cancer, disease progression, and response to prostate cancer therapies."
Commercial
7ms
Mdxhealth signs research collaboration with University of Oxford to assess the correlation of the GPS test with prostate cancer progression following treatment for localized prostate cancer (MDxHealth Press Release)
"MDxHealth...announced a research collaboration with the University of Oxford to investigate the correlation between the Genomic Prostate Score (GPS) test and prostate cancer progression following treatment for localized prostate cancer."
Licensing / partnership
|
Oncotype DX Genomic Prostate Score® Assay
8ms
Cigna expands commercial and medicare advantage coverage to include Mdxhealth’s Select mdx for prostate cancer test (MDxHealth Press Release)
"MDxHealth...announced that Cigna has expanded commercial and Medicare Advantage coverage to include the Company’s Select mdx for Prostate Cancer test. With the addition of Select mdx, Cigna will now provide insurance coverage across mdxhealth’s full menu of precision diagnostic cancer tests, including its Confirm mdx and Genomic Prostate Score (GPS) tests."
Reimbursement
|
Oncotype DX Genomic Prostate Score® Assay • SelectMDx
12ms
Foundational LCD covers Select mdx for prostate cancer (MDxHealth Press Release)
"MDxHealth...received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA. Select mdx will be reimbursed throughout the U.S. for Medicare patients who meet coverage conditions under the foundational Local Coverage Determination (LCD) for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer."
Reimbursement
|
SelectMDx
1year
MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test (GlobeNewswire)
"MDxHealth SA...announced that UnitedHealthcare will cover the mdxhealth Genomic Prostate Score (GPS) test (formerly Oncotype DX GPS) under UnitedHealthcare’s commercial policies to assist with treatment decisions for individuals newly diagnosed with localized prostate cancer and meeting coverage criteria."
Reimbursement
|
Oncotype DX Genomic Prostate Score® Assay
over1year
Mdxhealth acquires Oncotype DX® GPS Prostate Cancer business from Exact Sciences and reports preliminary half year 2022 results (MDxHealth Press Release)
"MDxHealth...announced it has entered into an asset purchase agreement with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation ('Exact Sciences'), to acquire the Oncotype DX® GPS (Genomic Prostate Score®) test from Exact Sciences along with most of its team of urology sales and marketing professionals. This addition further solidifies the Company’s leadership in the precision diagnostics urology market."
M&A
|
Oncotype DX Genomic Prostate Score® Assay
almost2years
Palmetto GBA’s MolDX issues foundational LCD covering the indication for SelectMDx for prostate cancer (MDxHealth Press Release)
"MDxHealth SA...announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Coverage Determination (LCD) for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer that covers the indication for our SelectMDx® for Prostate Cancer test. The foundational LCD identifies evidence supporting the clinical utility of our SelectMDx test and, when the LCD becomes effective on July 3, 2022, is expected to support coverage of our test for qualified Medicare patients throughout the United States."
Reimbursement
|
SelectMDx